Medscape5h
More Evidence Supports PRLs as a Potential Therapeutic Target in MS
A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...
MedPage Today on MSN2d
Tenecteplase No Longer Off-Label as Stroke Lytic
Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...
MedPage Today on MSN1d
Omalizumab Superior to Oral Immunotherapy for Kids With Multi-Food Allergy
Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food ...
GlobalData on MSN2d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
PMLive1d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
Genentech receives FDA acceptance for Gazyva sBLA
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...
Contract Pharma1d
Genentech’s TNKase Approved by FDA for Treatment of Strokes
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Healio22h
Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Fierce Pharma2d
Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic stroke
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
PharmiWeb3h
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...
BioSpace1d
Roche Continues Regulatory Run With Acute Stroke Expansion for Heart Attack Drug
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...